Christos Vaklavas

机构：University of Utah, Huntsman Cancer Institute · ORCID：0000-0002-9919-2748

发表论文 159 篇 · 总被引 3096 次 · h-index 29

代表论文

• A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results (2024 · Annals of Oncology · 被引 69)
• Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial (2024 · Nature Medicine · 被引 50)
• Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring (2025 · American Society of Clinical Oncology Educational Book · 被引 32)
• Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial (2024 · Nature Medicine · 被引 15)
• TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer (2024 · JCO Precision Oncology · 被引 9)
• H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC). (2024 · Journal of Clinical Oncology · 被引 6)